Alkem Laboratories enters into exclusive license agreement with Johns Hopkins University

31 Jan 2022 Evaluate

Johns Hopkins University, on behalf of its School of Medicine (JHU) and Alkem Laboratories (Alkem) have entered into an exclusive license agreement for the development and commercialization of JHU's novel target and technology that will help patients with colorectal cancer. This technology, a novel target, will serve as a bona fide biomarker and antagonist in human colorectal cancer based on angiogenesis and inflammation.

Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.

Alkem Laboratories Share Price

5427.70 -72.05 (-1.31%)
30-Dec-2025 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.80
Dr. Reddys Lab 1265.95
Cipla 1491.40
Zydus Lifesciences 902.30
Lupin 2081.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×